News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Purple Biotech Ltd ADR
(NQ:
PPBT
)
0.4000
+0.0200 (+5.26%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Purple Biotech Ltd ADR
< Previous
1
2
3
Next >
PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024
August 16, 2024
PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
July 25, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
July 02, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Why Purple Biotech (PPBT) Shares Are Trading Lower
July 01, 2024
Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds.
Via
Benzinga
Purple Biotech: Q3 Earnings Insights
November 21, 2023
Via
Benzinga
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
July 10, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
July 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
June 27, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
June 10, 2024
Via
Benzinga
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
June 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
May 31, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
May 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
May 23, 2024
Via
Benzinga
PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024
May 21, 2024
PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
May 10, 2024
Via
Benzinga
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
April 25, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
April 22, 2024
Via
Benzinga
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
March 28, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
March 14, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
March 05, 2024
PPBT stock results show that Purple Biotech met analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
February 27, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
February 13, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
February 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 10, 2024
Via
Benzinga
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
December 20, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
December 14, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 11, 2023
Via
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
December 11, 2023
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 11, 2023
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!
Via
InvestorPlace
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.